Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06494904 · ClinicalTrials.gov registry record · Phase 3
Standard Versus High Dose ED-Initiated Buprenorphine Induction
A Phase 3 study of Opioid Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 5
- Study locations
NCT06494904 is a Phase 3 study of Opioid Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 360 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06494904, a Phase 3 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.
Conditions Studied
Interventions
- DRUG Buprenorphine
Study Locations (5)
California
- Highland Hospital - Oakland
- San Leandro Hospital - San Leandro
Maine
- Maine Medical Center - Portland
New Jersey
- Cooper University Hospital - Camden
Utah
- University of Utah Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06494904
The ClinicalTrials.gov registry entry for NCT06494904 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (92% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.
NCT06494904 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Maine, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06494904 about?
NCT06494904 is a clinical study titled "Standard Versus High Dose ED-Initiated Buprenorphine Induction". This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post rand...
What is the current status of trial NCT06494904?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2024-12-06. Estimated completion is 2028-12.
What conditions does trial NCT06494904 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06494904?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT06494904?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06494904 being conducted?
This trial has 5 study locations across California, Maine, New Jersey, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Buprenorphine for Individuals in Jail
RECRUITING · Phase 3
-
Treating Polysubstance Use Using a Novel Digital Technology
RECRUITING · Phase 3
-
High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)
RECRUITING · Phase 3
-
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
RECRUITING · Phase 3
-
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
RECRUITING · Phase 3
-
Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.